BERKELEY HEIGHTS, N.J.--(BUSINESS WIRE)--Cyclacel Pharmaceuticals, Inc. (NASDAQ:CYCC)(NASDAQ:CYCCP) announced today the presentation of eight posters highlighting preclinical data of Cyclacel’s cell cycle inhibitors, sapacitabine, seliciclib and CYC116, at the upcoming American Association of Cancer Research (AACR) Annual Meeting. The meeting is being held in the San Diego Convention Center in San Diego, CA from April 12-16, 2008.
